Search
Elsubrutinib
go.drugbank.com/drugs/DB18850InvestigationalWith Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State). … Elsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants
QazCovid-in
go.drugbank.com/drugs/DB16441InvestigationalThe QazCovid-in vaccine, an inactivated vaccine, was developed and tested in the Kazakh Research Institute for Biological Safety Problems[L30628]. … It demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357), and will now be undergoing upcoming Phase III trials[L30633, L30638].
OSI-7904L
go.drugbank.com/drugs/DB05457InvestigationalCurrent treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor.
PHB-050
go.drugbank.com/drugs/DB32061ExperimentalPHB-050 is a novel, next-generation anti-IgE antibody designed to block IgE from binding to mast cells, while also rapidly reducing circulating IgE and inhibiting its production. … [L54988] It is under investigation for the treatment of multiple atopic diseases, including food allergies, asthma, and atopic dermatitis.[L54988]
Abdavomeran
go.drugbank.com/drugs/DB15695Investigationalfrom T4 fibritin to increase immunogenicity. … [L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein together with a "foldon" trimerization domain derived
Human Embryonic Stem Cell-derived M Cell
go.drugbank.com/drugs/DB15734InvestigationalIMRCs are similar to MSCs in terms of their capacity for self-renewal and tri-lineage differentiation. … CAStem is composed of immunity- and matrix-regulatory cells (IMRCs), also known as M cells, which can be administered through injection.
Golotimod
go.drugbank.com/drugs/DB05475InvestigationalIt has been shown to stimulate T-lymphocyte differentiation, macrocytic phagocytosis, and specific immune responses, and enhance IL-2 and INF-g production. … Due to this preferential activation of Th1 cytokine production, SCV-07 may show utility in treatment of tuberculosis. It can be administered orally or subcutaneously.
V-SARS
go.drugbank.com/drugs/DB15812InvestigationalThis therapeutic concept was applied to the development of V-SARS, which heat inactivates the plasma, and packages it into a once-daily pill form. … [COVID-19 convalescent plasma] is currently being acquired from recovered COVID-19 patients and used as prophylaxis for the virus.
Flizasertib
go.drugbank.com/drugs/DB21613InvestigationalThe usage of the INN stem '-sertib' in the name indicates that Flizasertib is a serine/threonine kinase inhibitor. … Flizasertib is under investigation in clinical trial NCT06602453 (A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse
IGN301
go.drugbank.com/drugs/DB05117ExperimentalIGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. … Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers).